Assessment of Structural and Functional Variability in Successive Autologous Platelet Formulations

Abstract

Autologous platelet formulations have become integral to regenerative medicine due to their capacity to deliver a concentrated pool of growth factors, cytokines, and cellular mediators essential for tissue repair and regeneration. Over time, advancements in preparation techniques have resulted in successive generations of platelet-based biomaterials, each exhibiting distinct structural and functional characteristics. This study provides a comprehensive assessment of variability across these formulations, focusing on differences in composition, fibrin architecture, cellular distribution, and biological activity. By synthesizing findings from established literature, the paper examines how preparation protocols—including centrifugation speed, activation methods, and leukocyte inclusion—affect the release kinetics of bioactive molecules and clinical outcomes. Comparative analysis reveals that first-generation formulations are characterized by rapid growth factor release, whereas later formulations demonstrate sustained release and enhanced scaffold properties. Furthermore, the presence of leukocytes and modifications in fibrin structure significantly influence inflammatory responses and tissue remodeling. The study identifies critical factors contributing to variability and highlights the absence of standardized protocols as a major challenge. The findings suggest that optimal formulation selection should be tailored to specific clinical applications rather than adopting a universal approach. This research contributes to a deeper understanding of platelet-based therapies and provides a framework for future optimization and innovation in regenerative medicine.

Keywords:

Autologous platelet formulations, platelet-rich plasma, platelet-rich fibrin, regenerative medicine, growth factors, fibrin matrix, leukocytes, tissue engineering

References

Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999;14:529‐535.

Antich‐Rossello M, Forteza‐Genestra MA, Monjo M, Ramis JM. Platelet‐derived extracellular vesicles for regenerative medicine. Int J Mol Sci. 2021;22:8580.

Carestia A, Mena HA, Olexen CM, et al. Platelets promote macrophage polarization toward pro‐inflammatory phenotype and increase survival of septic mice. Cell Rep. 2019;28(4):896‐908.

Castro AB, Andrade C, Li X, Pinto N, Teughels W, Quirynen M. Impact of g force and timing on the characteristics of platelet‐rich fibrin matrices. Sci Rep. 2021;11:6038.

Cavallo C, Roffi A, Grigolo B, et al. Platelet‐rich plasma: the choice of activation method affects the release of bioactive molecules. Biomed Res Int. 2016;2016:6591717.

Chemali M, Laurent A, Scaletta C, et al. Burn center organization and cellular therapy integration: managing risks and costs. J Burn Care Res. 2021;42:911‐924.

Choukroun J, Adda F, Schoeffer C, Vervelle A. PRF: une opportunité en paro‐implantologie. Implant Dent. 2001;42:55‐62.

Choukroun J, Ghanaati S. Reduction of relative centrifugation force within injectable platelet‐rich‐fibrin (PRF) concentrates advances patients' own inflammatory cells, platelets and growth factors: the first introduction to the low speed centrifugation concept. Eur J Trauma Emerg Surg. 2018;44:87‐95.

Diesen DL, Lawson JH. Bovine thrombin: history, use, and risk in the surgical patient. Vascular. 2008;16 Suppl 1:S29‐S36.

Dohan DM, Choukroun J, Diss A, et al. Platelet‐rich fibrin (PRF): a second‐generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:e37‐e44.

Dohan DM, Choukroun J, Diss A, et al. Platelet‐rich fibrin (PRF): a second‐generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:e51‐e55.

Dohan Ehrenfest DM, Bielecki T, Jimbo R, et al. Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence‐based answer comparing a pure platelet‐rich plasma (P‐PRP) gel and a leukocyte‐ and platelet‐rich fibrin (L‐PRF). Curr Pharm Biotechnol. 2012;13:1145‐1152.

Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet‐rich plasma (P‐PRP) to leucocyte‐ and platelet‐rich fibrin (L‐PRF). Trends Biotechnol. 2009;27:158‐167.

Fijnheer R, Pietersz RN, de Korte D, et al. Platelet activation during preparation of platelet concentrates: a comparison of the platelet‐rich plasma and the buffy coat methods. Transfusion. 1990;30:634‐638.

Fiorentino S, Roffi A, Filardo G, Marcacci M, Kon E. European definitions, current use, and EMA stance of platelet‐rich plasma in sports medicine. J Knee Surg. 2015;28:51‐54.

Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res. 2010;89:219‐229.

Gudbrandsdottir S, Hasselbalch HC, Nielsen CH. Activated platelets enhance IL‐10 secretion and reduce TNF‐alpha secretion by monocytes. J Immunol. 2013;191:4059‐4067.

Kobayashi E, Fluckiger L, Fujioka‐Kobayashi M, et al. Comparative release of growth factors from PRP, PRF, and advanced‐PRF. Clin Oral Investig. 2016;20:2353‐2360.

Linke B, Schreiber Y, Picard‐Willems B, et al. Activated platelets induce an anti‐inflammatory response of monocytes/macrophages through cross‐regulation of PGE(2) and cytokines. Mediators Inflamm. 2017;2017:1463216.

Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet‐rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85:638‐646.

Maxson S, Lopez EA, Yoo D, Danilkovitch‐Miagkova A, Leroux MA. Concise review: role of mesenchymal stem cells in wound repair. Stem Cells Transl Med. 2012;1:142‐149.

Miron RJ, Chai J, Fujioka‐Kobayashi M, Sculean A, Zhang Y. Evaluation of 24 protocols for the production of platelet‐rich fibrin. BMC Oral Health. 2020; 20:310.

Qian Y, Han Q, Chen W, et al. Platelet‐rich plasma derived growth factors contribute to stem cell differentiation in musculoskeletal regeneration. Front Chem. 2017;5:89.

Sánchez‐González DJ, Méndez‐Bolaina E, Fau‐Trejo‐Bahena NI, Trejo‐Bahena NI. Platelet‐rich plasma peptides: key for regeneration. Int J Pept. 2012;2012:532519.

Schar MO, Diaz‐Romero J, Kohl S, Zumstein MA, Nesic D. Platelet‐rich concentrates differentially release growth factors and induce cell migration in vitro. Clin Orthop Relat Res. 2015;473:1635‐1643.

Sharif PS, Abdollahi M. The role of platelets in bone remodeling. Inflamm Allergy Drug Targets. 2010;9:393‐399.

Steller D, Herbst N, Pries R, Juhl D, Hakim SG. Impact of incubation method on the release of growth factors in non‐Ca(2+)‐activated PRP, Ca(2+)‐activated PRP, PRF and A‐PRF. J Craniomaxillofac Surg. 2019;47:365‐372.

Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet‐rich plasma. Am J Sports Med. 2011;39:2135‐2140.

Wang X, Fok MR, Pelekos G, Jin L, Tonetti MS. In vitro and ex vivo kinetic release profile of growth factors and cytokines from leucocyte‐ and platelet‐rich fibrin (L‐PRF) preparations. Cell. 2022;11:2089.

Weibrich G, Kleis WK, Hafner G. Growth factor levels in the platelet‐rich plasma produced by 2 different methods: curasan‐type PRP kit versus PCCS PRP system. Int J Oral Maxillofac Implants. 2002;17:184‐190.

Weibrich G, Kleis WK, Hitzler WE, Hafner G. Comparison of the platelet concentrate collection system with the plasma‐rich‐in‐growth‐factors kit to produce platelet‐rich plasma: a technical report. Int J Oral Maxillofac Implants. 2005; 20:118‐123.